The Neurological Institute, Columbia University, 710 W. 168th Street, New York, NY 10032, USA.
Neurology. 2011 Nov 29;77(22):1965-71. doi: 10.1212/WNL.0b013e31823a0c7f. Epub 2011 Nov 16.
To describe the natural history of clinical and laboratory features associated with the m.3243A>G mitochondrial DNA point mutation. Natural history data are needed to obtain prognostic information and for clinical trial planning.
We included 85 matrilineal relatives from 35 families with at least 2 visits in this prospective cohort study. Thirty-one were fully symptomatic with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), and 54 were carrier relatives. Evaluations included standardized questionnaires (medical history and daily living functioning), physical examination, neuropsychological testing, and a battery of imaging and laboratory tests. We evaluated changes in clinical and laboratory features over time and survival. Outcomes are reported over a follow-up period of up to 10.6 years (mean 3.8 ± 2.2 years for patients and 5.5 ± 3.0 for carrier relatives).
Neurologic examination, neuropsychological testing, and daily living scores significantly declined in all patients with MELAS, whereas no significant deterioration occurred in carrier relatives. Cerebral MRI scores declined significantly in patients with MELAS. Magnetic resonance spectroscopy estimates of lactate in the lateral ventricles increased over time, and high lactate was associated with increased mortality. Symptom onset in childhood often was associated with worse outcome. Patients with MELAS had a greater death rate than carrier relatives.
Patients with MELAS carrying the m.3243A>G mutation show a measurable decline in clinical and imaging outcomes. It is hoped that these data will be helpful in anticipating the disease course and in planning clinical trials for MELAS.
描述与 m.3243A>G 线粒体 DNA 点突变相关的临床和实验室特征的自然病史。需要自然病史数据来获得预后信息和进行临床试验规划。
我们纳入了这项前瞻性队列研究中 35 个家系的 85 位母系亲属,这些家系至少有 2 次就诊。其中 31 位是完全有症状的线粒体脑肌病、乳酸酸中毒和卒中样发作(MELAS)患者,54 位是携带者亲属。评估包括标准化问卷(病史和日常生活功能)、体格检查、神经心理学测试以及一系列影像学和实验室检查。我们评估了随时间推移临床和实验室特征的变化以及生存率。研究结果报告了长达 10.6 年(MELAS 患者的平均随访时间为 3.8 ± 2.2 年,携带者亲属为 5.5 ± 3.0 年)的随访期。
所有 MELAS 患者的神经系统检查、神经心理学测试和日常生活评分均显著下降,而携带者亲属则没有明显的恶化。MELAS 患者的脑 MRI 评分显著下降。侧脑室的磁共振波谱估计的乳酸水平随时间增加,高乳酸与死亡率增加相关。儿童期起病常与预后较差相关。MELAS 患者的死亡率高于携带者亲属。
携带 m.3243A>G 突变的 MELAS 患者的临床和影像学结局有明显下降。希望这些数据有助于预测疾病进程并为 MELAS 规划临床试验。